New FDA breakthrough-drug category--implications for patients.
Publication
, Journal Article
McClellan, M; Sigal, E
Published in: The New England journal of medicine
July 2014
Duke Scholars
Published In
The New England journal of medicine
DOI
EISSN
1533-4406
ISSN
0028-4793
Publication Date
July 2014
Volume
371
Issue
1
Start / End Page
87 / 88
Related Subject Headings
- United States Food and Drug Administration
- Investigational New Drug Application
- Humans
- General & Internal Medicine
- Drugs, Investigational
- Drug Approval
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
McClellan, M., & Sigal, E. (2014). New FDA breakthrough-drug category--implications for patients. The New England Journal of Medicine, 371(1), 87–88. https://doi.org/10.1056/nejmc1405337
McClellan, Mark, and Ellen Sigal. “New FDA breakthrough-drug category--implications for patients.” The New England Journal of Medicine 371, no. 1 (July 2014): 87–88. https://doi.org/10.1056/nejmc1405337.
McClellan M, Sigal E. New FDA breakthrough-drug category--implications for patients. The New England journal of medicine. 2014 Jul;371(1):87–8.
McClellan, Mark, and Ellen Sigal. “New FDA breakthrough-drug category--implications for patients.” The New England Journal of Medicine, vol. 371, no. 1, July 2014, pp. 87–88. Epmc, doi:10.1056/nejmc1405337.
McClellan M, Sigal E. New FDA breakthrough-drug category--implications for patients. The New England journal of medicine. 2014 Jul;371(1):87–88.
Published In
The New England journal of medicine
DOI
EISSN
1533-4406
ISSN
0028-4793
Publication Date
July 2014
Volume
371
Issue
1
Start / End Page
87 / 88
Related Subject Headings
- United States Food and Drug Administration
- Investigational New Drug Application
- Humans
- General & Internal Medicine
- Drugs, Investigational
- Drug Approval
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences